2025/01/28 by Bowen Jing, Jing Wang, Jing, Bowen +1
Medicine · #Computer Vision and Pattern Recognition (cs.CV) #FOS: Computer and information sciences #FOS: Physical sciences #MRI in cancer diagnosis #Medical Imaging Techniques and Applications #Medical Physics (physics.med-ph) #Radiomics and Machine Learning in Medical Imaging
paper · pdf · doi:10.48550/arxiv.2502.00051
openalex publication_date 2025/01/28 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28
Rationale and Objectives: Early prediction of pathological complete response (pCR) can facilitate personalized treatment for breast cancer patients. To improve prediction accuracy at the early time point of neoadjuvant chemotherapy, we proposed a two-stage dual-task learning strategy to train a deep neural network for early prediction of pCR using early-treatment magnetic resonance images. Methods: We developed and validated the two-stage dual-task learning strategy using the dataset from the national-wide, multi-institutional I-SPY2 clinical trial, which included dynamic contrast-enhanced magnetic resonance images acquired at three time points: pretreatment (T0), after 3 weeks (T1), and after 12 weeks of treatment (T2). First, we trained a convolutional long short-term memory network to predict pCR and extract the latent space image features at T2. At the second stage, we trained a dual-task network to simultaneously predict pCR and the image features at T2 using images from T0 and T1. This allowed us to predict pCR earlier without using images from T2. Results: The conventional single-stage single-task strategy gave an area under the receiver operating characteristic curve (AUROC) of 0.799 for pCR prediction using all the data at time points T0 and T1. By using the proposed two-stage dual-task learning strategy, the AUROC was improved to 0.820. Conclusions: The proposed two-stage dual-task learning strategy can improve model performance significantly (p=0.0025) for predicting pCR at the early stage (3rd week) of neoadjuvant chemotherapy. The early prediction model can potentially help physicians to intervene early and develop personalized plans at the early stage of chemotherapy.